immunochemotherapy

It is reported today that the contract has been signed for immunochemotherapy at Samsung BioLogics.

Although a proportion of these patients can be cured with immunochemotherapy alone but they are more likely to require radiation therapy than patients with DLBCL.

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci.

The predictive value of MCL immunophenotype on PFS and OS may have been surpassed by intensified frontline immunochemotherapy.

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. European Journal of Haematology, 86(2), 124-128.

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial.

DLBCLs thus can be divided by GEP or various IHC algorithms into GCB-like and activated B-cell (ABC)-like subtypes [Table 1], with the latter having a significantly poorer outcome than the GCB group.[7] These molecular subtypes are associated with different outcomes, even after the introduction of immunochemotherapy.[8] The characteristic features of GCB and ABC DLBCL are tabulated in [Table 1].

In addition, recent progress in lymphoma immunochemotherapy means that patients may have a better outcome if treated using a multidisciplinary approach comprising a monoclonal antibody (rituximab, which is specific for CD20-positive B lymphoma cells), less intensive chemotherapy, radiotherapy, and surgical intervention (where needed) [10-13].

Treatment with immunochemotherapy is offered for most patients, while radiation therapy and stem cell transplantation are used in selected patients [8].